Monopar Therapeutics Inc.

Monopar Therapeutics Initiates Phase 1a Trial of uPAR-Targeted Radiopharmaceutical MNPR-101-Lu in Advanced Cancers

- Monopar Therapeutics has commenced a Phase 1a clinical trial for MNPR-101-Lu, a novel radiopharmaceutical targeting urokinase plasminogen activator receptor (uPAR) in advanced solid tumors. - The open-label, dose-escalation study will initially enroll patients already participating in the MNPR-101-Zr imaging trial to identify those most likely to benefit from the therapy. - MNPR-101-Lu aims to selectively target and kill cancer cells expressing uPAR, which is found in various tumor types, while minimizing damage to healthy tissue. - This trial is potentially the world's first clinical trial of a uPAR-targeted therapeutic radiopharmaceutical, representing a significant advancement in targeted cancer therapy.